• Mashup Score: 1

    ASCO recently published new guidance on systemic therapy for tumor control in well-differentiated metastatic gastrointestinal and pancreatic neuroendocrine tumors in the Journal of Clinical Oncology. A companion Q and A article in the JCO-OP addresses some of the questions that clinicians may face as they implement these recommendations into clinical practice, including the role of somatostatin receptors and observation, definition of terms used within the guideline, considerations related to therapy options for G3 NETs, and future direction in research and treatment. ASCO also plans to address recommendations on the topic of symptom control of GEP-NETs in a forthcoming guideline

    Tweet Tweets with this article
    • Now available: new guideline update Q&A on systemic therapy for tumor control in well-differentiated metastatic #GEP-NETs: https://t.co/zMYk7h1ry5 #gicsm

  • Mashup Score: 0
    Cutaneous Malignancies - 1 year(s) ago

    Is sunscreen and annual skin cancer screening for everyone? Is gene expression profile (GEP) of clinical use in skin cancer patients?

    Tweet Tweets with this article
    • 📍 Is sunscreen and annual skin #cancer screening for everyone? Is #gene expression profile of clinical use in skin cancer patients? #GEP #MedEd #CME #Surgery #MedTwitter 🖥️ https://t.co/5cgQBoKUUN https://t.co/YcKmue1UbQ

  • Mashup Score: 0
    Cutaneous Malignancies - 1 year(s) ago

    Is sunscreen and annual skin cancer screening for everyone? Is gene expression profile (GEP) of clinical use in skin cancer patients?

    Tweet Tweets with this article
    • 📍 Is sunscreen and annual skin #cancer screening for everyone? Is gene expression profile of clinical use in skin cancer patients? #GEP #MedEd #CME #Surgery #MedTwitter 🖥️ https://t.co/8IMX4hoNIC https://t.co/SpWk6vJYnW

  • Mashup Score: 2
    Cutaneous Malignancies - 1 year(s) ago

    Is sunscreen and annual skin cancer screening for everyone? Is gene expression profile (GEP) of clinical use in skin cancer patients?

    Tweet Tweets with this article
    • 📍 Is sunscreen and annual skin #cancer screening for everyone? Is gene expression profile of clinical use in skin cancer patients? #GEP #MedEd #CME #Surgery 🖥️ https://t.co/B2yAQtKozZ https://t.co/e7ZSAa1HZK

  • Mashup Score: 0
    Cutaneous Malignancies - 1 year(s) ago

    Is sunscreen and annual skin cancer screening for everyone? Is gene expression profile (GEP) of clinical use in skin cancer patients?

    Tweet Tweets with this article
    • 📍 Is sunscreen and annual skin #cancer screening for everyone? Is gene expression profile of clinical use in skin cancer patients? #GEP #MedEd #CME #OncTwitter 🖥️ https://t.co/IIcCY6yads https://t.co/0QKqFRSDRb

  • Mashup Score: 0

    Garching / Munich, September 06, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second phase III clinical trial, COMPOSE, in advanced neuroendocrine tumors (GEP-NETs) will be presented at the upcoming ESMO Congress from September 9-13, 2022, in Paris. The start of patient treatment in…

    Tweet Tweets with this article
    • Design of our second phase 3 clinical trial, COMPOSE, with our lead radiopharmaceutical candidate, ITM-11, for the treatment of high grade #GEP-NETs to be presented at #ESMO2022 Congress from September 9-13 in Paris. For further details visit: https://t.co/kXCDoBBjbx https://t.co/t0RJHWi5Vb